Zura Bio Ltd (ZURA)
Zura Bio develops antibody medicines for autoimmune and inflammatory diseases, and has no approved products yet. It last closed at $1.03 on Nov 17, down 4.17% on the day. The average 12-month price target from 3 analysts is $7.67 (+640.7% from the last close), with a high of $10.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $114K, the largest $114K.
Key Stats
Last 12 monthsNot reported for this period.
From ZURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ZURA in the past 90 days. The average target is $7.67, with a high of $10.00 and a low of $5.00, compared with the last close of $1.03.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Oppenheimer | Maintained | Buy | $5 |
| Nov 10 | Guggenheim | Target lowered | Buy | $20 → $8 |
| Nov 9 | Wedbush | Target lowered | Buy | $22 → $10 |
| Aug 12 | Wedbush | Target raised | Buy | $15 → $22 |
| Aug 12 | Guggenheim | Maintained | Buy | $20 |
Technical Analysis
The stock is 188% below its 20 day and 268% below its 50 day average. It is 386% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $1.03, and the nearest resistance the Pivot R1 at $1.08.
| RSI (14) | 24.94 | Oversold below 30 | Oversold |
| MACD | -0.83 | Below its signal line | Bearish |
| Stochastic | 5.0 | Near the bottom of its range | Oversold |
| ADX (14) | 26.1 | Trending down | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -106.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −74.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.47 | Typical daily range, 45.0% of price |
| RSI (14) | 27.16 | Oversold below 30 | Oversold |
| MACD | -0.71 | Below its signal line | Bearish |
| Stochastic | 9.4 | Near the bottom of its range | Oversold |
| ADX (14) | 22.4 | Weak trend | |
| Williams %R | -98.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -220.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −80.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.95 | Typical daily range, 91.5% of price |
What happened before
See how ZURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ZURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in ZURA in the last 90 days.
Dark Pool
30DZURA Institutional Ownership
Full report →- ▲66 buying vs 42 selling
- ▼Held by funds -3.8 pts
- ▲Funds holding +27
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 122 | 95 | +28.4% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 72.0% | 75.7% | −3.8 pts |
| New / increased | 33 / 33 | 26 / 32 | +13.8% |
| Reduced / sold out | 36 / 6 | 19 / 24 | −2.3% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZURA is in one of them and how their past ZURA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZURA in an article yet. Here's the latest on the wider market.
About Zura Bio
Zura Bio is a biotechnology company based in La Jolla, California, that develops antibody medicines for people with autoimmune and inflammatory diseases. Its tibulizumab candidate is designed to block two immune signals, IL-17A and BAFF, within a single molecule. The company also has crebankitug and torudokimab, which target other immune pathways. Tibulizumab is in two Phase 2 trials, in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, and no Zura Bio medicine is yet approved for sale.
- Headquarters
- La Jolla, CA


